Hologic, Inc. (HOLX)

Market Cap	18.13B
Revenue (ttm)	3.99B
Net Income (ttm)	701.50M
Shares Out	232.27M
EPS (ttm)	2.92
PE Ratio	26.77
Forward PE	18.28
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,240,367
Open	78.28
Previous Close	78.57
Day's Range	77.60 - 78.49
52-Week Range	67.59 - 84.67
Beta	0.99
Analysts	Buy
Price Target	89.91 (+15.21%)
Earnings Date	Nov 4, 2024

About HOLX

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis ass...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Jun 21, 1990
• Employees: 6,990
• Stock Exchange: NASDAQ
• Ticker Symbol: HOLX
• Website: https://www.hologic.com

Financial Performance

In 2023, Hologic's revenue was $4.03 billion, a decrease of -17.12% compared to the previous year's $4.86 billion. Earnings were $456.00 million, a decrease of -64.98%.

Analyst Forecast

According to 11 analysts, the average rating for HOLX stock is "Buy." The 12-month stock price forecast is $89.91, which is an increase of 15.21% from the latest price.

Price Target

$89.91

(15.21% upside)

Analyst Consensus: Buy